Thus far, Pfizer's obesity efforts have crashed and burned. Last year, the pharmaceutical giant threw in the towel on ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. The COVID-19 vaccine and ...
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. Eddie Bauer to close all North ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results